Category: Ejecting Technologies

Ejecting Technologies – Ejecting.net

Global Inkjet Heads Ejection Technology Market 2020 Segment Overview, Company Profiles, Regional Analysis and Forecast 2025

The MarketWatch News Department was not involved in the creation of this content. Nov 24, 2020 (CDN Newswire via Comtex) — Global Inkjet Heads Ejection Technology Market 2020 by Company, Type and Application, Forecast to 2025[1] contains point by point data which enlarge understanding, scope, and application of this market. The report provides an in-depth analysis of industry- and economy-wide...

READ MORE Global Inkjet Heads Ejection Technology Market 2020 Segment Overview, Company Profiles, Regional Analysis and Forecast 2025

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 23, 2020 /PRNewswire/ — Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance®(empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction – with and without diabetes – regardless of chronic kidney disease status at baseline. These results were shared today as an...

READ MORE New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Axon Therapies Announces Positive Results From First-In-Human Clinical Study in Late-Breaking Clinical Trial Session At 2020 Virtual HFSA Conference

Interim results from Axon Therapies’ First-in-Human Trial of the Satera Ablation System (11 HFpEF patients at 1- and 3-month follow-up) Interim results from Axon Therapies’ First-in-Human Trial of the Satera Ablation System (11 HFpEF patients at 1- and 3-month follow-up) NEW YORK, Oct. 9, 2020 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing one of the root...

READ MORE Axon Therapies Announces Positive Results From First-In-Human Clinical Study in Late-Breaking Clinical Trial Session At 2020 Virtual HFSA Conference

SCIEX Debuts Breakthrough Acoustic Ejection Mass Spectrometry Technology at ASMS 2019

ATLANTA–(BUSINESS WIRE[1])–SCIEX[2], a global leader in life science analytical technologies, introduces Acoustic Ejection Mass Spectrometry (AEMS) technology, a milestone for the future of high-throughput quantification, at ASMS 2019. AEMS technology, incorporating the Open Port Interface (OPI) and Acoustic Droplet Ejection (ADE), has received unprecedented enthusiasm from collaborators, leading SCIEX to introduce the technology ahead of commercialization. SCIEX intends to bring...

READ MORE SCIEX Debuts Breakthrough Acoustic Ejection Mass Spectrometry Technology at ASMS 2019

Generated by Feedzy